A composition for treating cancer comprising a combination of an anti-CD26 antibody and another anticancer agent

摘要

An object of the present invention is to provide a new mesothelioma treatment method with high safety. CD26 is overexpressed in mesothelioma and is considered highly safe. It was clarified that the anti-CD26 antibody was combined with the standard therapy cisplatin-pemetrexide combination to enhance the growth inhibitory effect of mesothelioma. Further, as a result of examining the effect of the combined use of humanized CD26 antibody and gemcitabine on the growth of mesothelioma cell line, the combined use of anti-CD26 antibody and gemcitabine has a high therapeutic effect and is excellent in safety. It has been found that a dermatoma treatment method can be provided. Furthermore, as a result of combining anti-CD26 antibody (YS110) and triptolide with a bivalent cross-linking agent in combination therapy using anti-CD26 antibody, a novel antibody drug that is very effective against CD26-positive malignant mesothelioma cells A complex (Y-TR1) was successfully obtained. [Selection figure] None